NXL — Nexalin Technology, Inc.

Nasdaq · Health Care · Health Care Equipment & Supplies · CIK 1527352 ·
Last close
$0.32
Market Cap
$6.95M
52W High
$0.64
52W Low
$0.31
ADV30
183,049
Next earnings
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health epidemic in the United States and China. The company offers Generation 1, an easy-to-administer medical device which utilizes bioelectronic medical technology to treat anxiety, insomnia, and depression without the need for drugs or psychotherapy; and Generation 2 and Generation 3 headset devices for the treatment of depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, opioid addiction, alcoholism, and chronic pain, as well as alzheimer's disease, and dementia. Nexalin Technology, Inc. is headquartered in Houston, Texas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Mar 2026 14,950 13,133 -2,119,902 -2,096,837 3,694,633 1,207,895 808,364
Dec 2025 171,895 150,866 -2,413,167 -2,376,546 4,635,319 654,783 887,333
Sep 2025 18,149 14,201 -2,345,631 -2,276,311 5,125,940 590,075 357,524
Jun 2025 70,588 47,750 -1,620,858 -1,580,987 6,563,982 431,320 600,584

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-5,244,432
Investing CF
$-96,070
Financing CF
$5,926,368
CapEx
$-152,553
Dividends Paid
Buybacks
EPS Diluted TTM
$-0.49
As of
2026-08-16

Balance + Analyst (yfinance extras)

Retained Earnings
$-94,964,249
Inventory
$179,489
Receivables
$43,004
ST Investments
$1,500,590
EBIT TTM
$-8,499,558
Pretax Income TTM
$-8,330,681
Interest Exp TTM
Analysts
1

Yahoo Snapshot (yfinance, live)

Total Revenue
$217,155
EBITDA
$-9,080,485
Free Cash Flow
$-2,533,424
Enterprise Value
$5,945,323
Total Cash
$1,004,958
Total Debt
$0
Shares Out
22,036,402
Trailing EPS
$-0.46
Book Value
$0.07
ROE
-240.3%
ROA
-119.2%
Div Yield

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Dec 2025 301,647 -8,390,881 -8,222,181 4,635,319 887,333 -4,957,658
Dec 2024 168,721 -7,754,646 -7,607,182 4,222,732 546,694 -3,944,390
Dec 2023 110,748 -5,696,296 -4,648,709 3,631,916 425,281 -3,835,384
Dec 2022 1,321,357 -1,833,031 -1,697,816 7,432,136 1,953,449 -2,215,699

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$-0.31

Peers — same industry

TickerNameMarket CapLastDaily %
NDRA ENDRA Life Sciences Inc. $6.84M $4.56
NVNO enVVeno Medical Corp $7.19M $10.35
SNOA Sonoma Pharmaceuticals, Inc. $6.42M $1.34
INBS INTELLIGENT BIO SOLUTIONS INC. $7.55M $2.50
CODX Co-Diagnostics, Inc. $7.63M $1.22

News headlines (Yahoo Finance, 1h cache)

Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Qu
2026-06-10 13:15 · Yahoo
EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of Life
2026-06-10 13:01 · Yahoo
Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomnia
2026-06-04 14:00 · Yahoo
Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal Trial
2026-05-19 12:30 · Yahoo
Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic Insomnia
2026-04-28 13:15 · Yahoo
Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 Enrollment
2026-04-22 13:35 · Yahoo
Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and China
2026-04-15 14:00 · Yahoo
Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21
2026-04-14 12:30 · Yahoo
Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female Adolescents
2026-04-09 11:47 · Yahoo
Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ Platform
2026-06-23 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.